Development and validation of a predictive score for chemoresistance in high-grade osteosarcoma at baseline.

ABSTRACT:

Objective

Histological tumor necrosis is the current indicator for the response of osteosarcoma after neoadjuvant chemotherapy. Chemoresistant tumors require close monitoring and adjustment of treatment. We aimed to develop a prediction score for chemoresistance in newly diagnosed osteosarcoma patients underwent neoadjuvant chemotherapy.

Materials and methods

Data from a registry-based cohort of high-grade osteosarcoma patients treated with neoadjuvant chemotherapy between January 2008 and October 2023 were used. Histological necrosis from surgical specimens was the reference standard. Clinical and MRI parameters at baseline were derived by risk regression analysis.

Results

From 139 patients, 93 (66.91%) were classified as chemoresistant (histological necrosis <90%).

SUBMITTER: Kanthawang T 

PROVIDER: S-EPMC12271180 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature